T1	Participants 81 117	patients with advanced breast cancer
T2	Participants 134 157	122 premenopausal women
T3	Participants 221 349	54 evaluable women treated with tamoxifen, 24% had an objective response, as compared with 21% of 53 women having an oophorectom
T4	Participants 560 658	5 months for 58 patients receiving tamoxifen and 25 months for 53 patients undergoing oophorectomy
T5	Participants 778 797	premenopausal women
